COMMUNIQUÉS West-GlobeNewswire

China SXT Pharmaceuticals, Inc. Announces Share Re-classification
23/03/2026
TAIZHOU, China, March 23, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (Nasdaq: SXTC) (the “Company” or “SXTC”), a specialty pharmaceutical company focusing on the research, development, manufacturing, [...]
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout
23/03/2026
First Interim Unblinding of Pivotal AML Trial Now Imminent — Potentially the Most Important Data Moment in Company History Early Blinded Results Show 40% Remission Rate Across Difficult-to-Treat Patient Population [...]
Pfizer et Valneva annoncent que le candidat vaccin contre la maladie de Lyme démontre une forte efficacité dans l’essai de Phase 3 VALOR
23/03/2026
Le candidat vaccin PF-07307405 (LB6V) a démontré une efficacité de plus de 70 % dans la prévention de la maladie de Lyme chez les personnes âgées de cinq ans et plus. Le candidat vaccin a été bien toléré, sans problème [...]
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy
23/03/2026
MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a [...]
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
23/03/2026
OPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines (PCVs) Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with Capvaxive ® (PCV21) and [...]
Kraig Biocraft Laboratories Increases R&D Capacity, as Project Atlas Breakthroughs Creating New Spider Silk Transgenics
23/03/2026
ANN ARBOR, Mich., March 23, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced a significant [...]
Novo Nordisk A/S - share repurchase programme
23/03/2026
Bagsværd, Denmark, 23 March 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group
23/03/2026
March 23, 2026 Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage [...]
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease
23/03/2026
New data show brain-volume preservation correlates with patient outcomes Long-term clinical data indicate 77.4 weeks (17.8 months) time saved with oral blarcamesine compared to ADNI 1 control group after 144 weeks (33.1 [...]
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer
23/03/2026
ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]
Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET
23/03/2026
BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
CDT Identifies Rare Disease Opportunities Through Sarborg Signature Analysis, Advancing Out-Licensing Strategy
23/03/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 23, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announces that it has completed initial signature mapping of its asset [...]
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
23/03/2026
Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025 $2.25B Moderna global settlement for infringement of lipid nanoparticle (LNP) delivery technology represents [...]
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement
23/03/2026
Company has the funding, business plan, leadership and infrastructure to propel achievement of upcoming commercial and clinical milestones MOUNTAIN VIEW, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“ [...]
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
23/03/2026
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon has earned a second of three potential $10 million near- [...]
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
23/03/2026
XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 Advancing potential first-in-class multi-specific, [...]
Trading in GN Store Nord shares by board members, executives and associated persons
23/03/2026
GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN [...]
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
23/03/2026
Ms. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (Nasdaq: KRYS), where she helped lead the U.S. launch of VYJUVEK®, supporting its growth from FDA [...]
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
23/03/2026
IRVINE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that a $15 million milestone payment due Tarsus has been achieved following regulatory approval of TP-03 ( [...]

Pages